ବାଇକାଲୁଟାମାଇଡ

ଉଇକିପିଡ଼ିଆ ରୁ
Jump to navigation Jump to search
ବାଇକାଲୁଟାମାଇଡ
Bicalutamide.svg
Bicalutamide 3D ball.png
Clinical data
PronunciationBicalutamide:
/bkəˈltəmd/ bye-kə-LOO-tə-myde[୨]
Casodex:
/ˈksdɛks/ KAY-soh-deks[୩]
Trade namesCasodex, Cosudex, Calutide, Calumid, Kalumid, others
SynonymsICI-176,334; ZD-176,334
AHFS/Drugs.commonograph
MedlinePlusa697047
data
Pregnancy
category
  • AU: D
  • US: X (Contraindicated)
Routes of
administration
By mouth[୧]
Drug classNonsteroidal antiandrogen
ATC code
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityWell-absorbed; absolute bioavailability unknown[୬]
Protein bindingRacemate: 96.1%[୧]
(R)-Isomer: 99.6%[୧]
(Mainly to albumin)[୧]
MetabolismLiver (extensively):[୪][୫]
Hydroxylation (CYP3A4)
Glucuronidation (UGT1A9)
Metabolites• Bicalutamide glucuronide
• Hydroxybicalutamide
• Hydroxybicalutamide gluc.
(All inactive)[୪][୧][୭][୮]
Elimination half-lifeAcute: 5.8 days[୯]
Chronic: 7–10 days[୧୦]
ExcretionFeces: 43%[୪]
Urine: 34%[୪]
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
ECHA InfoCard100.126.100 Edit this at Wikidata
Chemical and physical data
FormulaC18H14F4N2O4S
Molar mass430.373 g/mol
3D model (JSmol)
ChiralityRacemic mixture (of (R)- and (S)-enantiomers)
Melting point୧୯୧ to ୧୯୩ °C (୩୭୬ to ୩୭୯ °F) (experimental)
Boiling point୬୫୦ °C (୧,୨୦୨ °F) (predicted)
Solubility in water0.005 mg/mL (20 °C)
 NYesY (what is this?)  (verify)

ବାଇକାଲୁଟାମାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Bicalutamide, ବିକ୍ରୟ ନାମ କାସୋଡେକ୍ସ/ Casodex) ଏକ ଆଣ୍ଡ୍ରୋଜେନ ବିରୋଧୀ (antiandrogen) ଔଷଧ ଯାହା ପ୍ରୋସ୍ଟେଟ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ନିମନ୍ତେ ଦିଆଯାଏ ।[୧୧] ମେଟାସ୍ଟାସିସ (metastatic) ହୋଇଥିବା ପ୍ରୋସ୍ଟେଟ କର୍କଟ ରୋଗରେ ବା ଓର୍କିଡେକ୍ଟୋମି (surgical removal of the testicles) କରାଯାଇଥିଲେ ଏହା ଗୋନାଡୋଟ୍ରପିନ-ରିଲିଜିଙ୍ଗ ହରମୋନ ଆନାଲଗ (gonadotropin-releasing hormone (GnRH) analogue) ସାଥିରେ ଦିଆଯାଏ ।[୧୨][୧୧][୧୩] ମହିଳାଙ୍କର ଅତ୍ୟଧିକ ବାଳ ବୃଦ୍ଧି (excessive hair growth) ହୋଇଥିଲେ ବାଇକାଲୁଟାମାଇଡ ଦିଆଯାଏ,[୧୪] ଟ୍ରାନ୍ସଜେଣ୍ଡର ମହିଳାଙ୍କର (transgender women) ହରମୋନ ଥେରାପିର (hormone therapy) ଏହା ଉପାଦାନ ଥାଏ,[୧୫] ପ୍ରିଆପିଜ୍ମ (priapism) ପ୍ରତିଷେଧ ନିମନ୍ତେ ଦିଆଯାଏ,[୧୬] ଓ ବାଳକମାନଙ୍କର ସମୟ ପୂର୍ବ ଯୌବନ ପ୍ରାପ୍ତି (early puberty) ରୋଗମାନଙ୍କ ନିମନ୍ତେ ଏହା ଦିଆଯାଏ ।[୧୭] ଏହି ଔଷଧ ପାଟିରେ (by mouth) ଦିଆଯାଏ ।[୧୧]

ଏହାର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ତନ ବୃଦ୍ଧି (breast enlargement), ସ୍ତନ ଯନ୍ତ୍ରଣା (breast tenderness) ଓ ଦେହ ଲାଲ ପଡ଼ିଯିବା (hot flashes) ଦେଖାଯାଏ ।[୧୧] ପୁରୁଷମାନଙ୍କର ମହିଳାତ୍ୱ (feminization) ପ୍ରକାଶ ପାଏ ଓ ସେମାନେ ଯୌନ କ୍ରିୟାହୀନ (sexual dysfunction) ହୋଇଯାଆନ୍ତି ।[୧୮] ମହିଳାମାନଙ୍କର ଅଳ୍ପ ପ୍ରତିକ୍ରିୟା ହେଲେ ମଧ୍ୟ ଏହା ବ୍ୟବ‌ହାର କରିବାକୁ ଏଫଡିଏ (Food and Drug Administration ବା FDA) ମନା କରେ ।[୧୯][୧୧] ଗର୍ଭାବସ୍ଥାରେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।[୧୧] ପ୍ରାୟ ୧% ଲୋକଙ୍କର ବାଇକାଲୁଟାମାଇଡ ଯୋଗୁ ଟ୍ରାନ୍ସାଆମିନେଜ ସ୍ତର ବୃଦ୍ଧି (elevated liver enzyme) ପାଏ ।[୨୦][୨୧] ଏହା ଯୋଗୁ କ୍ୱଚିତ୍ ଯକୃତ୍ ବିଷକ୍ରିୟା (liver damage),[୧୧]ଫୁସଫୁସ ବିଷକ୍ରିୟା (lung toxicity) ଦେଖାଯାଇପାରେ ।[୬] ଯକୃତ ପରିବର୍ତ୍ତନ ଓ କ୍ଷତି ସଙ୍କଟ କମ୍ ଥିଲେ ମଧ୍ୟ ଚିକିତ୍ସା ସମୟରେ ଲିଭର ଫଙ୍କସନ ଟେଷ୍ଟ (monitoring of liver enzyme) କରିବାକୁ ଉପଦେଶ ଦିଆଯାଏ ।[୧୧]

ଆଧାର[ସମ୍ପାଦନା]

  1. ୧.୦ ୧.୧ ୧.୨ ୧.୩ ୧.୪ Cockshott ID (2004). "Bicalutamide: clinical pharmacokinetics and metabolism". Clinical Pharmacokinetics. 43 (13): 855–878. doi:10.2165/00003088-200443130-00003. PMID 15509184. These data indicate that direct glucuronidation is the main metabolic pathway for the rapidly cleared (S)-bicalutamide, whereas hydroxylation followed by glucuronidation is a major metabolic pathway for the slowly cleared (R)-bicalutamide.
  2. Finkel R, Clark MA, Cubeddu LX (2009). Pharmacology. Lippincott Williams & Wilkins. pp. 481–. ISBN 978-0-7817-7155-9.
  3. Sifton DW, PDR Staff (2002). PDR Drug Guide for Mental Health Professionals. Thomson/PDR. ISBN 978-1-56363-457-4.
  4. ୪.୦ ୪.୧ ୪.୨ ୪.୩ ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; LemkeWilliams2008 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
  5. ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; GrosseCampeau2013 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
  6. ୬.୦ ୬.୧ ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; Dart2004 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
  7. Dole EJ, Holdsworth MT (1997). "Nilutamide: an antiandrogen for the treatment of prostate cancer". The Annals of Pharmacotherapy. 31 (1): 65–75. doi:10.1177/106002809703100112. PMID 8997470. page 67: Currently, information is not available regarding the activity of the major urinary metabolites of bicalutamide, bicalutamide glucuronide, and hydroxybicalutamide glucumnide.
  8. Schellhammer PF (September 2002). "An evaluation of bicalutamide in the treatment of prostate cancer". Expert Opinion on Pharmacotherapy. 3 (9): 1313–28. doi:10.1517/14656566.3.9.1313. PMID 12186624. The clearance of bicalutamide occurs pre- dominantly by hepatic metabolism and glucuronidation, with excretion of the resulting inactive metabolites in the urine and faces.
  9. ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; Skidmore-Roth2013 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
  10. ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; JordanFurr2010 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
  11. ୧୧.୦ ୧୧.୧ ୧୧.୨ ୧୧.୩ ୧୧.୪ ୧୧.୫ ୧୧.୬ ୧୧.୭ "Bicalutamide". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
  12. Wass JA, Stewart PM (28 July 2011). Oxford Textbook of Endocrinology and Diabetes. OUP Oxford. pp. 1625–. ISBN 978-0-19-923529-2.
  13. Shergill I, Arya M, Grange PR, Mundy AR (2010). Medical Therapy in Urology (in ଇଂରାଜୀ). Springer Science & Business Media. p. 40. ISBN 9781848827042.
  14. Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B (22 January 2009). Evidence-Based Dermatology. John Wiley & Sons. pp. 529–. ISBN 978-1-4443-0017-8.
  15. Gooren, LJ (31 March 2011). "Clinical practice. Care of transsexual persons". The New England Journal of Medicine. 364 (13): 1251–7. doi:10.1056/nejmcp1008161. PMID 21449788.
  16. Yuan J, Desouza R, Westney OL, Wang R (2008). "Insights of priapism mechanism and rationale treatment for recurrent priapism". Asian Journal of Andrology. 10 (1): 88–101. doi:10.1111/j.1745-7262.2008.00314.x. PMID 18087648.
  17. Jameson JL, De Groot LJ (25 February 2015). Edndocrinology: Adult and Pediatric. Elsevier Health Sciences. pp. 2425–2426, 2139. ISBN 978-0-323-32195-2.
  18. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW (2010). "Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life". The Journal of Sexual Medicine. 7 (9): 2996–3010. doi:10.1111/j.1743-6109.2010.01902.x. PMID 20626600.
  19. Shapiro J (12 November 2012). Hair Disorders: Current Concepts in Pathophysiology, Diagnosis and Management, An Issue of Dermatologic Clinics. Elsevier Health Sciences. pp. 187–. ISBN 1-4557-7169-4.
  20. "Casodex® (bicalutamide) Tablets" (PDF). FDA.
  21. Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer" (PDF). Drugs. 66 (6): 837–50. doi:10.2165/00003495-200666060-00007. PMID 16706554.